



CNMV
Markets Directorate General
C/ Edison núm. 4
28006 Madrid

Madrid, September 8, 2020

In accordance with article 227 of the recast Spanish Securities Market Act (*texto refundido de la Ley del Mercado de Valores*), is hereby reported the following:

OTHER RELEVANT INFORMATION

The Company announces the creation of a new Virology Unit, to research, develop and provide medicines for viral diseases, for which there are, up to today, no effective treatments.

The current priority of this Unit is focused on finding an effective treatment for SARS-CoV-2. In this sense, the Company is at the clinical development phase with its molecule, plitidepsin, as a treatment against COVID-19.

PharmaMar is currently running the APLICOV-PC clinical trial to evaluate the safety and efficacy of plitidepsin at three different dose levels. The results of this first trial are expected to be available during the month of October this year.

Please find attached press release that will be distributed to the media today.

PharmaMar sets up a new Virology Unit

- This new Unit has been started with the aim of researching, developing and providing treatments for viral diseases for which there are no effective treatments.
- The Unit will be led by Belén Sopesén, Ph.D., Director of Corporate Affairs at PharmaMar.
- José María Jimeno, M.D. Ph.D., will take up the clinical direction as VP Global Head of the Virology Unit.

Madrid, September 8th, 2020. – PharmaMar (MSE:PHM) has announced today the creation of a new Virology Unit, to research, develop and provide medicines for viral diseases, for which there are, up to today, no effective treatments.

The current priority of this Unit is focused on finding an effective treatment for SARS-CoV-2. In this sense, the Company is at the clinical development phase with its molecule, plitidepsin, as a treatment against COVID-19.

PharmaMar is currently running the APLICOV-PC^{1,2} clinical trial to evaluate the safety and efficacy of plitidepsin at three different dose levels. The results of this first trial are expected to be available during the month of October this year.

Plitidepsin has demonstrated in different preclinical studies its efficacy against SARS-CoV-2 and other types of coronaviruses. PharmaMar's molecule has been investigated in "*in vitro*" trials at several leading research centers worldwide, including the National Biotechnology Center of the Spanish National Research Council (CNB-CSIC)³, directed by Dr. Luis Enjuanes; the Institute of Emerging Pathogens at Mount Sinai Hospital in New York, with Dr. Adolfo García Sastre; Germans Trias i Pujol Hospital in Barcelona, directed by Dr. Bonaventura Clotet; and the Institut Pasteur in Korea⁴.

¹ Spanish Clinical Trials Registry: APL-D-002-20 <https://reec.aemps.es/reec/public/detail.html>

² ClinicalTrials.gov: NCT04382066

<https://clinicaltrials.gov/ct2/show/NCT04382066?term=plitidepsin&draw=2&rank=8>

³ Press Release from PharmaMar: http://pharmamar.com/wp-content/uploads/2020/03/NdP-Resultados-Aplidin_coronavirus.pdf

⁴ Press Release from PharmaMar: http://pharmamar.com/wp-content/uploads/2020/07/NdP_Resultados_in_vitro_plitidespina_Corea_OK.pdf

These pre-clinical studies show that *in vitro* plitidepsin eliminates COVID-19 viral load at nanomolar concentrations. A molecule with nanomolar potency, such as plitidepsin, obtains the same effectiveness as a molecule with micromolar potency, but with a dose more than a thousand times lower than the latter.

As **José María Fernández, Ph.D.**, President of PharmaMar, explains, "*the world is experiencing different types of virus pandemics in different geographic areas. They are becoming increasingly important and are having a huge social and economic impact. At present, we live with viruses in animal species that are susceptible to jump species, ending up affecting human beings. For this reason, we need to be prepared to fight the viruses that are currently affecting and seriously impacting society, along with the viruses that could appear in the near future. What has happened with SARS-CoV-2, could happen again.*"

It should be noted that plitidepsin is currently approved for the treatment of patients with Multiple Myeloma in Australia, therefore this drug has already gone through all the phases of clinical trials in humans, so its level of tolerability and adverse effects are known.

Appointments for the new Virology Unit

The new Virology Unit will be led by **Belén Sopesén, Ph.D.**, in Pharmacy from the Complutense University of Madrid with a Management Development program at IESE.

Linked to pharmaceutical research and development since 1997, she joined the PharmaMar group in 2005, and since 2020 has been the Group's Director of Corporate Affairs. She was previously Director of Market Research, and has also held management positions in two Group Companies as General Manager and Director representing PharmaMar at Xylazel and as General Manager of Noscira S.A., another biotechnology company in the Group dedicated to R&D of innovative treatments for neurodegenerative diseases.

She is also a Director representing PharmaMar at Sylentis and an independent Director at another biotechnology company.

PharmaMar has also announced the appointment of **José María Jimeno, M.D. Ph.D.**, as VP Global Head of the Company's new unit.

Dr. José Jimeno, who holds a degree in Medicine, with the specialty in Medical Oncology from the University of Zaragoza and a Ph.D. in Pharmacy from the Autonomous University of Barcelona, will assume the Clinical Development at



PharmaMar's new Virology Unit, this reinforcing the commitment to both COVID-19 patients and R&D. In the words of **José María Jimeno**, *"the clinical management of the Virology Unit at PharmaMar is a great challenge and an opportunity to develop the therapeutic potential offered by molecules of a marine origin. With our extensive collection of samples, we will now be able to test solutions against other viruses and other emerging pathologies."*

For his part, Dr. Jimeno explained that, *"due to the growing evolution of viruses in animals, scientists are very concerned with the possibility of viruses leaping species into humans, as has happened in the current pandemic."*

Dr. Jimeno, who joined PharmaMar in July, has a broad background in medical oncology and clinical development. From 1994 to 2008 leading the team as VP of Clinical Development at PharmaMar, therefore being an expert in plitidepsin's use and behavior.

"We have great expectations for this new Virology Unit at PharmaMar. The Company is facing an exciting challenge to provide innovative and effective solutions to meet unmet medical needs for patients suffering from viral diseases such as COVID-19, along with other emerging viruses," said **José María Fernández**, President of PharmaMar.

Legal warning

This press release does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.

About PharmaMar

Headquartered in Madrid, PharmaMar is a biopharmaceutical company, focused on oncology and committed to research and development which takes its inspiration from the sea to discover molecules with antitumor activity. It is a company that seeks innovative products to provide healthcare professionals with new tools to treat cancer. Its commitment to patients and to research has made it one of the world leaders in the discovery of antitumor drugs of marine origin.

PharmaMar has a pipeline of drug candidates and a robust R&D oncology program. It develops and commercializes Yondelis® in Europe and has other clinical-stage programs under development for several types of solid cancers: Zepzelca™ (lurbinectedin, PM1183), PM184 and PM14. With subsidiaries in Germany, Italy, France, Switzerland, Belgium, Austria and the United States. PharmaMar wholly owns other companies: GENOMICA, a molecular diagnostics company; Sylentis, dedicated to researching therapeutic applications of gene silencing (RNAi). To learn more about PharmaMar, please visit us at www.pharmamar.com.

Media Contact:

Alfonso Ortín – Communications Director aortin@pharmamar.com Mobile: +34 609493127

Miguel Martínez-Cava – Communication Manager mmartinez-cava@pharmamar.com Mobile: +34

606597464

Álvaro Mateo - Communication Manager amateo@pharmamar.com Mobile: +34 650726009

Phone: +34 918466000

Capital Markets & Investor Relations:

José Luis Moreno– Capital Markets & Investor Relations Director

María Marín de la Plaza – Capital Markets & Investor Relations

investorrelations@pharmamar.com

Phone: +34 914444500



Or please visit our website at www.pharmamar.com